Remove oncology Podcasts
article thumbnail

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

PharmaTech

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

article thumbnail

Merck on trends in oncology: the pharmaphorum podcast

pharmaphorum

Episode 45 of the pharmaphorum podcast heard from Dr Stuart Hill, how he’s seen the oncology landscape change and which of those he sees holding the most potential to improve patient outcomes. The post Merck on trends in oncology: the pharmaphorum podcast appeared first on.

52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biotech Insight podcast: Overcoming planning challenges in oncology

pharmaphorum

The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular focus on oncology. The post Biotech Insight podcast: Overcoming planning challenges in oncology appeared first on.

52
article thumbnail

Listen: The plight of the VC, Gilead’s latest setback, & more M&A

STAT

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We also take a look at Gilead Sciences’ struggle to turn itself into an oncology company and the latest biotech to get bought out by a major pharma firm.

251
251
article thumbnail

Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion

STAT

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. As so-called radiopharmaceuticals make headlines in oncology, we explore their fascinating scientific backstory and the biotech gold rush to make them. And who’s to blame for a biotech blow-up?

277
277
article thumbnail

Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise

STAT

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. And why are venture capitalists so optimistic?

266
266
article thumbnail

AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

STAT

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology.

251
251